Compound: METAXALONE
SMILES: O=C1OC(COc2cc(cc(c2)C)C)CN1
InChIKey: IMWZZHHPURKASS-UHFFFAOYSA-N
Synonyms: METAXALONE, 1665-48-1, Skelaxin, Zorane, Methaxalonum, Metaxalon, Methoxolone, AHR-438, 2-Oxazolidinone, 5-[(3,5-dimethylphenoxy)methyl]-, Metaxalona, 5-[(3,5-Dimethylphenoxy)methyl]-1,3-oxazolidin-2-one, Metassalone, Metaxalonum, Flexura, 5-(3,5-Xyloloxymethyl)oxazolidin-2-one, CL 39,148, 5-[(3,5-Xylyloxy)methyl]-2-oxazolidinone, 2-Oxazolidinone, 5-((3,5-xylyloxy)methyl)-, DTXSID3023269, 5-((3,5-Dimethylphenoxy)methyl)-2-oxazolidinone, 5-((3,5-Xylyloxy)methyl)-2-oxazolidinone, NSC-170959, 1NMA9J598Y, 2-Oxazolidinone, 5-((3,5-dimethylphenoxy)methyl)-, NSC170959, DTXCID103269, 5-(3,5-dimethylphenoxymethyl)-1,3-oxazolidin-2-one, 2-Oxazolidinone, 5-[(3,5-xylyloxy)methyl]-, 5-[(3,5-Dimethylphenoxy)methyl]-2-oxazolidinone, 5-((3,5-Dimethylphenoxy)methyl)-1,3-oxazolidin-2-one, Metaxal, metaxalone tablet, RefChem:55595, 216-777-6, 5-((3,5-Dimethylphenoxy)methyl)oxazolidin-2-one, Metaxolone, Metazalone, Metazolone, Metaxalonum [Latin], Metassalone [DCIT], Metaxalonum [INN-Latin], Metaxalona [INN-Spanish], AHR 438, NSC 170959, 5-[(3,5-dimethylphenoxy)methyl]oxazolidin-2-one, MFCD00867700, MLS003106749, s3730, NCGC00095116-01, 5-(3,5-dimethylphenoxymethyl)-2-oxazolidinone, Metaxalona [Spanish], CAS-1665-48-1, Metaxalone [USAN:INN:BAN], HSDB 3236, SR-05000001978, EINECS 216-777-6, BRN 0884592, UNII-1NMA9J598Y, .meta.Xalone, .meta.Zalone, .meta.Zolone, .meta.Xalon, Skelaxin (TN), Metaxalone (Standard), Spectrum_001741, METAXALONE [MI], SpecPlus_000656, Metaxalone (USP/INN), METAXALONE [INN], Spectrum2_000548, Spectrum3_001666, Spectrum4_000612, Spectrum5_001685, METAXALONE [HSDB], METAXALONE [USAN], METAXALONE [VANDF], METAXALONE [MART.], METAXALONE [USP-RS], METAXALONE [WHO-DD], Oprea1_438855, SCHEMBL34908, BSPBio_003451, KBioGR_001164, KBioSS_002221, DivK1c_006752, SPECTRUM1504229, SPBio_000595, CHEBI:6797, GTPL7609, orb1308030, CHEMBL1079604, METAXALONE [ORANGE BOOK], Metaxalone, >=98% (HPLC), HY-B0678R, KBio1_001696, KBio2_002221, KBio2_004789, KBio2_007357, KBio3_002671, GLXC-07875, HMS1922H07, HMS2093C22, HMS5082G05, METAXALONE [USP MONOGRAPH], Pharmakon1600-01504229, HY-B0678, MSK11343, Tox21_111428, WLN: T5MVOTJ D1OR C1 E1, 2-Oxazolidinone,5-xylyloxy)methyl]-, CCG-39592, EBC-06028, NSC758703, STL450994, STL451511, AKOS009035315, Tox21_111428_1, DB00660, FD25129, FS-3218, NSC-758703, NCGC00095116-02, NCGC00095116-03, NCGC00095116-05, SMR001821638, SY052772, SBI-0052859.P002, 2-Oxazolidinone,5-dimethylphenoxy)methyl]-, DB-043656, M2578, NS00000535, 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, C07934, D00773, EN300-119839, AB00053284_04, F079268, Q6823309, SR-05000001978-1, SR-05000001978-3, BRD-A94709349-001-02-6, BRD-A94709349-001-03-4, BRD-A94709349-001-08-3, Z106952910, 5-((3,5-dimethylphenoxy)methyl)-4,5-dihydrooxazol-2-ol, 5-[(3,5-Dimethylphenoxy)methyl]-1,3-oxazolidin-2-one #, 5-{[(3,5-dimethylphenyl)oxy]methyl}-1,3-oxazolidin-2-one, 5-[(3,5-dimethylphenoxy)methyl]-4,5-dihydro-1,3-oxazol-2-ol, Metaxalone, United States Pharmacopeia (USP) Reference Standard
Theoretical properties:
molecular_formula: C12H15NO3
molecular_weight: 221.25 g/mol
exact_mass: 221.10519334 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 3
heavy_atom_count: 16
topological_polar_surface_area: 47.6 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White to almost white crystalline powder
color: White to almost white crystalline powder
odor: Odorless
boiling_point: BP: 223 °C at 1.5 mm Hg
solubility: Freely soluble in chloroform; soluble in methanol and 95% ethanol; practically insoluble in ether
Descriptions:
pubchem: Metaxalone is an aromatic ether.
chembl: METAXALONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Metaxalone, sold under the brand name Skelaxin, is a muscle relaxant medication used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions. Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is a moderately strong muscle relaxant, with relatively low incidence of side effects.
Common side effects include nausea, vomiting, drowsiness, and central nervous system (CNS) side effects, such as dizziness, headache, and irritability.
The metabolism of metaxalone involves enzymes CYP1A2 and CYP2C19 in the cytochrome P450 system.  Because many medications are metabolized by enzymes in this system, precaution must be taken when administering it with other medications involving the P450 system to avoid interactions.
Because of the potential for side effects, this drug is considered high risk in the elderly.